A protein called PriC allows DNA replication to proceed in Escherichia coli when the complex that usually initiates this process is compromised.

ATX-559, a first-in-class oral DHX9 inhibitor, is being evaluated in a Phase 1/2 study with a focuson advanced or metastatic ...

This study proposes a new mechanism by which Chd1 senses and responds to DNA unwrapping via EDBL engagement to suppress ...

Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall ...

Among animals, the contribution of Dicer’s helicase to recognition and elimination of viral double-stranded RNA (dsRNA) varies from phylum to phylum. Vertebrate Dicers show no helicase activity, while ...

Detailed price information for Repare Therapeutics Inc (RPTX-Q) from The Globe and Mail including charting and trades.

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, ...

Here we report the characterization of the human DEAD-box RNA helicase DDX26. The gene is composed of 14 exons distributed over an extension of 8,123 bp of genomic sequence and encodes a transcript of ...

suggesting cooperation between closed-loop assembly and eIF4B/helicase functions. Remarkably, depleting eukaryotic translation initiation factor 4G (eIF4G), the scaffold subunit of eukaryotic ...